@article{GordonDaneshianBouwstraetal.2015,
  author    = {Gordon, Sarah and Daneshian, Mardas and Bouwstra, Joke and Caloni, Francesca and Constant, Samuel and Davies, Donna E. and Dandekar, Gudrun and Guzman, Carlos A. and Fabian, Eric and Haltner, Eleonore and Hartung, Thomas and Hasiwa, Nina and Hayden, Patrick and Kandarova, Helena and Khare, Sangeeta and Krug, Harald F. and Kneuer, Carsten and Leist, Marcel and Lian, Guoping and Marx, Uwe and Metzger, Marco and Ott, Katharina and Prieto, Pilar and Roberts, Michael S. and Roggen, Erwin L. and Tralau, Tewes and van den Braak, Claudia and Walles, Heike and Lehr, Claus-Michael},
  title     = {Non-animal models of epithelial barriers (skin, intestine and lung) in research, industrial applications and regulatory toxicology},
  series = {ALTEX: Alternatives to Animal Experimentation},
  volume    = {32},
  journal   = {ALTEX: Alternatives to Animal Experimentation},
  number    = {4},
  doi       = {10.14573/altex.1510051},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-144275},
  pages     = {327-378},
  year      = {2015},
  abstract  = {Models of the outer epithelia of the human body namely the skin, the intestine and the lung have found valid applications in both research and industrial settings as attractive alternatives to animal testing. A variety of approaches to model these barriers are currently employed in such fields, ranging from the utilization of ex vivo tissue to reconstructed in vitro models, and further to chip-based technologies, synthetic membrane systems and, of increasing current interest, in silico modeling approaches. An international group of experts in the field of epithelial barriers was convened from academia, industry and regulatory bodies to present both the current state of the art of non-animal models of the skin, intestinal and pulmonary barriers in their various fields of application, and to discuss research-based, industry-driven and regulatory-relevant future directions for both the development of new models and the refinement of existing test methods. Issues of model relevance and preference, validation and standardization, acceptance, and the need for simplicity versus complexity were focal themes of the discussions. The outcomes of workshop presentations and discussions, in relation to both current status and future directions in the utilization and development of epithelial barrier models, are presented by the attending experts in the current report.},
  language  = {en}
}
@article{ShityakovSalvadorPastorinetal.2015,
  author    = {Shityakov, Sergey and Salvador, Ellaine and Pastorin, Giorgia and F{\"o}rster, Carola},
  title     = {Blood-brain barrier transport studies, aggregation, and molecular dynamics simulation of multiwalled carbon nanotube functionalized with fluorescein isothiocyanate},
  series = {International Journal of Nanomedicine},
  volume    = {10},
  journal   = {International Journal of Nanomedicine},
  doi       = {10.2147/IJN.S68429},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-149233},
  pages     = {1703-1713},
  year      = {2015},
  abstract  = {In this study, the ability of a multiwalled carbon nanotube functionalized with fluorescein isothiocyanate (MWCNT-FITC) was assessed as a prospective central nervous system-targeting drug delivery system to permeate the blood-brain barrier. The results indicated that the MWCNT-FITC conjugate is able to penetrate microvascular cerebral endothelial monolayers; its concentrations in the Transwell® system were fully equilibrated after 48 hours. Cell viability test, together with phase-contrast and fluorescence microscopies, did not detect any signs of MWCNT-FITC toxicity on the cerebral endothelial cells. These microscopic techniques also revealed presumably the intracellular localization of fluorescent MWCNT-FITCs apart from their massive nonfluorescent accumulation on the cellular surface due to nanotube lipophilic properties. In addition, the 1,000 ps molecular dynamics simulation in vacuo discovered the phenomenon of carbon nanotube aggregation driven by van der Waals forces via MWCN-TFITC rapid dissociation as an intermediate phase.},
  language  = {en}
}
@article{GlaserSchultheisMolletal.2015,
  author    = {Glaser, Jan and Schultheis, Martina and Moll, Heidrun and Hazra, Banasri and Holzgrabe, Ulrike},
  title     = {Antileishmanial and Cytotoxic Compounds from Valeriana wallichii and Identification of a Novel Nepetolactone Derivative},
  series = {Molecules},
  volume    = {20},
  journal   = {Molecules},
  number    = {4},
  doi       = {10.3390/molecules20045740},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-125320},
  pages     = {5740-5753},
  year      = {2015},
  abstract  = {The chloroform extract of Valeriana wallichii (V. wallichii) rhizomes was investigated to elucidate the structures responsible for reported antileishmanial activity. Besides bornyl caffeate (1, already been reported by us previously), bioassay-guided fractionation resulted in two additional cinnamic acid derivatives 2-3 with moderate leishmanicidal activity. The structure of a novel nepetolactone derivative 4 having a cinnamic acid moiety was elucidated by means of spectral analysis. To the best of our knowledge villoside aglycone (5) was isolated from this plant for the first time. The bioassay-guided fractionation yielded two new (compounds 6-7) and two known valtrates (compounds 8-9) with leishmanicidal potential against Leishmania major (L. major) promastigotes. In addition, β-bisabolol (10), α-kessyl alcohol (11), valeranone (12), bornyl isovalerate (13) and linarin-2-O-methylbutyrate (14) were identified. This is the first report on the isolation of 4'-demethylpodophyllotoxin (15), podophyllotoxin (16) and pinoresinol (17) in V. wallichii. In total thirteen known and four new compounds were identified from the extract and their cytotoxic and antileishmanial properties were evaluated.},
  language  = {en}
}